A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease.

Trial Profile

A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Polycystic liver disease
  • Focus Therapeutic Use
  • Acronyms SOM230
  • Most Recent Events

    • 18 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
    • 18 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2018.
    • 01 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top